The European Pharmacopoeia (Ph. Eur.) is a publication that sets out the quality standards for medicines in Europe. One of its key monographs is for tablets, which are a widely used dosage form for administering active pharmaceutical ingredients (APIs). The Ph. Eur. monograph for tablets, specifically monograph 0478, provides a comprehensive framework for ensuring the quality of tablets. In this article, we will explore the details of this monograph and what it means for the pharmaceutical industry.
The "better" rating for the current Monograph 0478 stems from three key modernizations: european pharmacopoeia ph eur monograph tablets 0478 better
While excellent, no monograph is perfect: The European Pharmacopoeia (Ph
Efforts to align Ph. Eur. standards with USP and JP to simplify global compliance. Continuous Manufacturing: The Ph
New guidance on how traditional monograph tests apply to innovative production methods. Elemental Impurities:
The European Pharmacopoeia (Ph. Eur.) is a single reference work for the quality control of medicines in Europe. It has legal binding force in all 38 member states and is used extensively in over 100 countries worldwide.